Independent association seen in unselected cohort in whom cTnI was measured, regardless of clinical indication for testing<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 10, 2023 (HealthDay News) — Cardiac troponin I (cTnI) concentration is associated with medium-term mortality in an unselected hospital population, according to a study published online Aug. 7 in Heart<\/em>.<\/p>\n Jonathan Hinton, from the University of Southampton in the United Kingdom, and colleagues conducted a prospective observational study including 20,000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital and in whom a high-sensitivity cTnI assay was measured.<\/p>\n Overall, 91.4 percent of the patients did not have a clinical indication for cTnI testing. The researchers found that 14.1 percent of patients died at a median of 809 days. If the cTnI concentration was above the upper limit of normal, mortality was significantly higher (45.3 versus 12.3 percent). In a multivariable analysis, log10<\/sub> cTnI concentration was independently associated with mortality (hazard ratio, 1.76). The relationship persisted in a landmark analysis, excluding deaths within 30 days.<\/p>\n “These findings suggest that a snapshot cTn in a hospital population may represent a biomarker of overall medium-term mortality,” the authors write.<\/p>\n One author disclosed ties to the biopharmaceutical industry.<\/p>\n